In this FUSCC‐BC prospective cohort, Luminal A (n = 375) and Luminal B (HER2‐, n = 559) subtypes account for 40%, which are lower than those in the MSKCC cohort; meanwhile, the FUSCC‐BC cohort includes more patients with Luminal B (HER2+, 13.52%, n = 260), HER2+ (18.46%, n = 355) and TNBC (19.03%, n = 366), respectively (Figure S1A). This evidence concerns the gene ERBB2 and breast cancer.